Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site. # Attivare Therapeutics Inc Harnessing the Power of AI to Activate The Immune System Against Cancer ## Sitemaps - [XML Sitemap](https://attivaretx.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine](https://attivaretx.com/attivare-therapeutics-awarded-6-6-million-grant-to-advance-durable-malaria-vaccine/) - Attivare Therapeutics, Inc. has announced the receipt of a $6.6 million grant from the Gates Foundation, supporting the advancement of a next-generation, long-lasting malaria vaccine, powered by the proprietary ATTimmune bioscaffold platform. This project is focused on providing an affordable, robust, and easily deployable solution for malaria in low- and middle-income countries, where challenges such - [Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine](https://attivaretx.com/attivare-therapeutics-awarded-6-6-million-grant-to-advance-durable-malaria-vaccine/) - Attivare Therapeutics, Inc. has announced the receipt of a $6.6 million grant from the Gates Foundation, supporting the advancement of a next-generation, long-lasting malaria vaccine, powered by the proprietary ATTimmune bioscaffold platform. This project is focused on providing an affordable, robust, and easily deployable solution for malaria in low- and middle-income countries, where challenges such - [AACR 2025 ATT-01 Poster](https://attivaretx.com/wp-content/uploads/AACR-2025-ATT-01.pdf#new_tab) - [AACR 2025 ATT-02 Poster](https://attivaretx.com/wp-content/uploads/AACR-2025-ATT-02.pdf#new_tab) - [Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025](https://www.biospace.com/press-releases/attivare-therapeutics-to-present-preclinical-data-for-att-01-and-att-02-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025#new_tab) - [Attivare Therapeutics Appoints David Sherris, Ph.D. as President, CEO, and Chairman](https://attivaretx.com/attivare-therapeutics-appoints-david-sherris-ph-d-as-president-ceo-and-chairman/) - NATICK, MA., Nov. 11, 2024 /Business Wire/ -- Attivare Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering new treatments for cancer and infectious diseases through its innovative immune-activating scaffold platform, ATTimmune, has named David Sherris, Ph.D. the company’s new President, Chief Executive Officer, and Chairman of the Board. Dr. Sherris’s appointment coincides with Attivare's progression - [Harvard’s Wyss Institute Gives Startup License to Use Newly-Developed Biomaterials](https://www.thecrimson.com/article/2024/10/15/Attivare-Cancer-Research/#new_tab) - [Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies](https://wyss.harvard.edu/news/attivare-licenses-wyss-institutes-immune-modulating-biomaterial-technology-to-advance-immunotherapies/#new_tab) ## Pages - [Home](https://attivaretx.com/) - [AACR 2025](https://attivaretx.com/aacr-2025/) - [Sherris-Appointment](https://attivaretx.com/sherris-appointment/) - ATTIVARE THERAPEUTICS ← BACK TO WEBSITE PRESS RELEASE Attivare Therapeutics Appoints David Sherris, Ph.D. as President, CEO, and Chairman NATICK, Mass. — November 12, 2024 | Business Wire Attivare Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering new treatments for cancer and infectious diseases through its innovative immune-activating scaffold platform, ATTimmune, has named David Sherris, - [Contact](https://attivaretx.com/contact/) - [Gates Foundation Grant](https://attivaretx.com/gates-foundation-grant/) - [NVIDIA Press Release](https://attivaretx.com/nvidia-press-release/) - [News](https://attivaretx.com/news/) - [et_pb_section fb_built="1" fullwidth="on" custom_padding_last_edited="on|tablet" _builder_version="4.19.4" _module_preset="default" custom_padding="0px||0px||true|false" custom_padding_tablet="0px||0px||true|false" custom_padding_phone="0px||0px||true|false" global_colors_info="{}"][et_pb_fullwidth_slider module_class="hero_banner" _builder_version="4.27.2" _module_preset="default" header_level="h1" header_font="|600|||||||" header_font_size="60px" header_line_height="1.41em" custom_button="on" button_text_size="40px" button_border_radius="66px" button_font="|600|||||||" button_use_icon="off" button_custom_padding="27.5px|90px|27.5px|90px|true|true" button_custom_padding_tablet="20px|60px|20px|60px|true|true" button_custom_padding_phone="17px|40px|17px|40px|true|true" button_custom_padding_last_edited="on|tablet" custom_padding="200px||200px||true|false" custom_padding_tablet="90px||90px||true|false" custom_padding_phone="90px||90px||true|false" custom_padding_last_edited="on|tablet" header_font_size_tablet="35px" header_font_size_phone="30px" header_font_size_last_edited="on|phone" button_text_size_tablet="30px" button_text_size_phone="20px" button_text_size_last_edited="on|phone" global_colors_info="{}"][et_pb_slide heading="News" button_link="#about" _builder_version="4.27.2" _module_preset="default" header_level="h1" background_enable_color="off" use_background_color_gradient="on" background_color_gradient_direction="270deg" background_color_gradient_stops="#15143e 0%|rgba(79,78,110,0.75) 100%" background_color_gradient_overlays_image="on" background_image="https://attivaretx.com/wp-content/uploads/hero-banner-bg.jpg" background_enable_image="on" global_colors_info="{}" sticky_transition="on"][/et_pb_slide][/et_pb_fullwidth_slider][/et_pb_section][et_pb_section fb_built="1" disabled_on="off|off|off" - [Home UPDATES](https://attivaretx.com/home-updates/) - [et_pb_section fb_built="1" fullwidth="on" custom_padding_last_edited="on|tablet" _builder_version="4.19.4" _module_preset="default" custom_padding="0px||0px||true|false" custom_padding_tablet="0px||0px||true|false" custom_padding_phone="0px||0px||true|false" global_colors_info="{}"][et_pb_fullwidth_slider module_class="hero_banner" _builder_version="4.27.4" _module_preset="default" header_level="h1" header_font="|600|||||||" header_font_size="60px" header_line_height="1.41em" custom_button="on" button_text_size="40px" button_border_radius="66px" button_font="|600|||||||" button_use_icon="off" button_custom_padding="27.5px|90px|27.5px|90px|true|true" button_custom_padding_tablet="20px|60px|20px|60px|true|true" button_custom_padding_phone="17px|40px|17px|40px|true|true" button_custom_padding_last_edited="on|tablet" custom_padding="200px||200px||true|false" custom_padding_tablet="90px||90px||true|false" custom_padding_phone="90px||90px||true|false" custom_padding_last_edited="on|tablet" header_font_size_tablet="35px" header_font_size_phone="30px" header_font_size_last_edited="on|phone" button_text_size_tablet="30px" button_text_size_phone="20px" button_text_size_last_edited="on|phone" global_colors_info="{}"][et_pb_slide heading="We develop cutting-edge immuno-therapeutics with unparalleled efficacy and durability, specifically designed to combat tumors with low immunogenicity." _builder_version="4.27.4" ## Categories - [Latest News](https://attivaretx.com/category/latest-news/) - [Media](https://attivaretx.com/category/media/)